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Effects of hemodialysis on platelet-derived thrombospondin. The ef-
fects on platelet-derived thrombospondin (TSP) of hemodialysis with a
cellulose membrane were studied in patients during routine hemodial-
ysis and in normal subjects using an ex vivo model. Plasma and
platelet-bound TSP were determined pre- and post-dialysis, in blood
entering and leaving the dialyzer after 1, 3, 5, 15, and 30 minutes of
dialysis, and in blood leaving the cx vivo module after 5, 10, 15, 20, and
25 minutes of perfusion. Plasma concentrations of /3-thromboglobulin
(I3TG) and thromboxane B2 (TxB2), and platelet membrane expression
of the a-granule protein GMP-l40, were also measured. Significant
increases in plasma concentrations of TSP and /3TG occurred between
the inlet and outlet of the dialyzer after 5, 15, and 30 minutes of dialysis,
accompanied by a slow, but significant, increase in their arterial plasma
concentrations. In contrast, initiation of dialysis was associated with an
immediate increase in plasma TxB2 concentration between the inlet and
outlet of the dialyzer and an abrupt increase in arterial plasma TxB,
concentration which plateaued at 250% of the pre-dialysis value after
five minutes. Transit of platelets through the dialyzer had no effect on
platelet-membrane-associated TSP or GMP-140. Plasma TSP and I3TG
concentrations at the outlet of the cx vivo module also increased
significantly during perfusion, but plasma TSP concentrations were
twofold greater than those during hemodialysis. In vitro stimulation of
platelets with thrombin and immunoblotting studies of platelet release
proteins showed reduced TSP release by platelets of hemodialysis
patients. These data demonstrate that dialyzer-induced platelet activa-
tion results in TSP release, suggesting that TSP can be a useful marker
of platelet activation during hemodialysis. However, platelets of hemo-
dialysis patients have an impaired ability to release TSP, most probably
due to a TSP storage pool deficiency.
Bleeding disorders are a well known complication of uremia
[1]. Although these disorders appear to be multifactorial in
origin, alterations in platelet function and defective platelet-
platelet or platelet-subendothelium interactions have been sug-
gested to play a role in their pathophysiology [2—4]. Hemodial-
ysis has been reported to improve uremic platelet dysfunction
[4, 5].
Thrombospondin (TSP) is a multifunctional, trimeric 440 kD
glycoprotein that is secreted during the release reaction of
human platelets [6—8]. Along with other constituents such as
/3-thromboglobulin (j3TG) and platelet factor 4, TSP is a major
component of platelet alpha granules [8], but also has been
found in a variety of other cell types, including flbroblasts,
endothelial cells, and monocytes [6].
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Although the pathophysiological role of TSP is still poorly
understood, it is a protein of remarkable functional diversity.
TSP has been reported to bind to heparin, fibrinogen, fi-
bronectin, plasminogen, collagen, and histidine-rich protein [8].
Recently, TSP has received considerable attention because of
its putative role as an adhesive glycoprotein in platelet aggre-
gation [9] and cytoadhesion [10]. To date, only a limited number
of studies have evaluated plasma TSP concentrations in disease
states. Significantly increased plasma levels of TSP have been
described in patients with acute myocardial infarction [11],
acute [12] and chronic [13] liver failure, and chronic renal
failure [13], although, with the exception of acute liver failure,
these increases were modest.
Since TSP may play an important role in platelet aggregation
and adhesion [9, 10], and because platelet function appears to
be modulated by hemodialysis [14, 15], we examined the impact
of hemodialysis on platelet TSP in vivo and using an cx vivo
model [16, 17]. Dialysis-induced changes in plasma TSP were
compared with those of two other markers of platelet activa-
tion, I3TG and thromboxane B2 (TxB2). In addition, flow
cytometric techniques were used to evaluate changes in cell
surface receptor binding of TSP and another alpha granule
protein, GMP-l40, that becomes combined with the plasma
membrane during the degranulation process [18].
Methods
Patients and control subjects
Changes in TSP during dialysis were evaluated in nine
patients with end-stage renal failure being treated with hemo-
dialysis for four hours thrice weekly. Details of the patients are
presented in Table 1. None of the patients was known to have
a hemostatic disorder and all had been free of infection for at
least one month prior to study. A careful history was obtained
from each subject to exclude use of aspirin-containing medica-
tions during the two weeks preceding the study. All patients
received aluminum hydroxide or calcium carbonate, vitamin
B12, and ferrous sulfate. Five of the patients were being treated
with recombinant human erythropoietin (1000 to 3000 U, three
times a week) for correction of anemia. Nine other, randomly
selected patients [5 male, 4 female; age 51 3 years; etiology of
renal failure: glomerulonephntis (2), polycystic kidney disease
(2), diabetic nephropathy (2), hypertensive nephrosclerosis (I),
and unknown (2); length of time on dialysis 40 13 months]
were studied before and after hemodialysis. Fifteen healthy
individuals (9 male, 6 female; age: 22 to 51 years) with normal
platelet count and hematocrit were included as normal control
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Table 1. Demographic details of patients participating in the hemodialysis studies
Patient
Etiology of
renal failure
Age
years Gender
Time on dialysis
months
Prior hemostatic
disordersa
Hct
%
Platelet count
103/j.diter
1 HTN 66 F 22 None 30 141
2 Unknown 63 M 37 None 32 195
3 GN 38 M 14 None 28 198
4 PCKD 50 F 3 GI bleeding (2) 29 313
5 Unknown 74 M 7 None 31 160
6 DN 44 M 44 None 29 244
7 Unknown 52 F 17 Epistaxis (28) 31 209
8 DN 56 F 128 Clotted shunt (18) 28 151
9 Unknown 41 M 20 None 32 296
Abbreviations are: ON, glomerulonephritis; DN, diabetic nephrosclerosis; HTN, hypertensive nephrosclerosis; PCKD, polycystic kidney
disease.
a Numbers in parentheses are months elapsed between occurrence of hemostatic disorder and this study
subjects. The study was approved by the Human Studies
Committee of the University of Louisville and informed con-
sent was obtained from each subject prior to the study.
In vivo study
All patients enrolled in this study underwent regular hemo-
dialysis treatment with dialyzers containing 1.5 m2 of hollow
fiber cellulose membrane (AM 300M, Asahi Medical, Tokyo,
Japan). Although all patients routinely reused their dialyzers,
only new dialyzers were used for this study. Anticoagulation
was achieved by means of a loading dose and constant infusion
of heparin (Elkins-Sinn, Cherry Hill, New Jersey, USA). For
each patient, a pharmacokinetic model [19] was used to calcu-
late the dose of heparin required to produce a twofold increase
in the whole blood partial thromboplastin time during dialysis.
The mean loading dose of heparin was 2056 IU (range: 1000 to
3500 IU) and the mean infusion rate 1472 lU/hr (range: 1000 to
2250 IU/hr). All treatments were performed using SPS 550
delivery systems (Baxter Healthcare, Deerfield, Illinois, USA)
and dialysate containing bicarbonate as the base repletion
agent. Blood flows were maintained at 250 mI/mm. Predialysis
blood samples were drawn from the access needle prior to
administration of heparin and after withdrawal of 3 ml of blood
to clear the needle of any plasma or tissue components acti-
vated by needle insertion. Further blood samples were obtained
alter 1, 3, 5, 15, and 30 minutes of dialysis from the inlet and
outlet blood lines of the dialyzer and from the arterial blood
line, post-dialysis (240 mm). Blood for platelet counts and
hematocrit was collected in sodium EDTA tubes and analyzed
on a model STKS Coulter Counter (Coulter Electronics, Hi-
aleah, Florida, USA). Blood samples for determination of TSP,
I3TG, and TxB2 were drawn into precooled plastic syringes
containing an anti-platelet activation cocktail composed of 0.9
mM EDTA, 10 mrt adenosine, 1 mri theophylline, and 1 mM
indomethacin in Tyrode's buffer, pH 7.5 (blood:anticoagulant =
7:1), and cooled on ice for 30 minutes before centrifugation. In
preliminary experiments, this cocktail was found to inhibit in
vitro platelet activation effectively. For flow cytometric studies
of spontaneous receptor expression, an aliquot of the blood
collected in the anti-platelet activation cocktail was immedi-
ately added to 2% paraformaldehyde in Tyrode's buffer, pH 7.5,
(blood:fixative = 1:1) and fixed at 4°C for one hour. For
experiments with thrombin stimulation of platelets, blood was
collected using ACD (NIH formula) as the anticoagulant.
Ex vivo study
The effect of cellulosic hollow fiber membranes on whole
blood platelet activation was evaluated using a previously
described ex vivo model which closely mimics hemodialysis
[16, 17]. Briefly, blood from healthy volunteers was used to
simultaneously perfuse modules containing 250 cm2 of cellulo-
sic membrane (Cuprophan, AKZO, Wuppertal, Germany) and a
tubing control at a rate of 5 ml/min. Under these conditions,
shear rates are similar to those found in routine hemodialysis.
Blood was anticoagulated by continuous infusion of heparin at
the tip of the access needle. The rate of heparin infusion was set
to achieve a concentration of 0.5 lU/mi, similar to that found in
hemodialysis. Samples were collected from the outlet of the
module and the tubing control into ice-cold polypropylene tubes
containing the anti-platelet activation cocktail after 5, 10, 15, 20
and 25 minutes of perfusion.
In vitro studies
Blood was collected from patients just before hemodialysis
and from normal controls into plastic syringes containing ACD
(ACD:blood = 1:7). Aliquots of 2.5 ml were immediately
distributed into 5 ml polypropylene tubes preloaded with throm-
bin (Sigma Chemical Co., St. Louis, Missouri, USA) in PBS
(200 p1) at final concentrations of 0.005 and 0.1 U/mI. I U of
hirudin (Sigma) in PBS was added to one tube as a baseline
control. All tubes were inverted once and platelet activation
allowed to proceed by incubating the tubes at 37°C for 10
minutes without agitation. Activation was stopped by adding
200 zl of ice-cold anti-platelet activation cocktail containing 1 U
hirudin. The tubes were then placed on crushed ice for a further
10 minutes before separating the plasma by centrifugation.
Measurement of zhrornbospondin, 13-thrombo globulin,
thromboxane B2
Platelet-poor plasma was prepared by centrifuging pre-cooled
blood samples at 4°C for 30 minutes at 1500 x g. The upper two
thirds of the supernatant was then removed carefully to avoid
disturbing the surface lipid layer. Platelet-rich plasma was
obtained by centrifugation at 150 x g for 10 minutes. To effect
platelet lysis, Triton X-100 was added at a final concentration of
0.5% and incubated at room temperature for 10 minutes. All
samples of platelet-poor plasma and lysed platelet-rich plasma
were frozen at —70°C and assayed within 30 days. TSP and I3TG
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were determined in duplicate using commercially available
enzyme immunoassays (Diagnostica Stago, Asnières, France)
with a sensitivity for TSP of 4 ng/ml and for /3TG of 10 ng/ml.
TxB2 levels were determined by radioimmunoassay (Amer-
sham, Arlington Heights, Illinois, USA) after extraction and
purification on C18-silica columns [20] (recovery 81 5%,
mean SD).
Flow cytometry
The following murine monoclonal antibodies were used:
fluorescein-(FITC)-conjugated anti-CD4I (Gentrak Inc., Ply-
mouth Meeting, Pennsylvania, USA), activation independent
and specific for the GPIIb-IIIa surface membrane complex;
phycoerythrin-(PE)-conjugated S12, directed against a-granule
protein GMP-140 (CD62) [181; and, TSP-B7 (Sigma), a mono-
clonal antibody specific for platelet TSP. TSP-B7 was further
purified by protein A affinity chromatography and biotinylated
with N-hydroxysuccimide-biotin-ester using standard methods.
An IgG1 monocional antibody (Sigma) that recognizes an
epitope on the CD5 molecule was biotinylated and used as
control for non-specific binding. PE-IgG control and PE-
streptavidin were purchased from Becton Dickinson Immuno-
cytometry Systems (San Jose, California, USA).
To determine TSP and GMP-140 associated with the surface
of non-stimulated platelets, fixed whole blood was centrifuged
at 150 x g for five minutes at 4°C. The platelet-rich plasma was
decanted and the platelets pelleted by centrifugation at 1500 x
g for five minutes. After washing off the fixative, platelets were
resuspended in Tyrodes's buffer (10 platelets/mi). To deter-
mine cell surface-associated TSP and GMP-140 following
thrombin activation, platelets were isolated from ACD-antico-
agulated blood by differential centrifugation and resuspended in
Tyrode's buffer, containing divalent cations (1 msi CaCl2, 0.5
mM MgCl2) at approximately iO platelets/mI. Thrombin (0.1
U/mi) was added and the platelets incubated at 37°C for 20
minutes without agitation. Activation was stopped by adding an
equal amount of 2% paraformaidehyde in Tyrode's buffer and
the cells allowed to fix for one hour at 4°C. The cells were then
washed and resuspended in the original volume of Tyrode's
buffer.
Saturating concentrations of biotin-conjugated TSP-B7, PE-
S12, or control antibody with 20 sl of the platelet suspension in
0,5 ml polypropylene tubes was for 30 minutes at 25°C. After
washing, PE-streptavidin and FITC-CD41 were added and the
incubation continued for a further 20 minutes. Platelets were
analyzed by means of a two-color method on a Cytofluorograph
us (Ortho Diagnostic Systems, Westwood, Massachusetts,
USA). To distinguish platelets from other cells in the light
scatter profile, the gate was set around those cells exhibiting a
high degree of green fluorescence, indicating the presence of the
platelet-specific CD41 complex (Fig. 1; >90% positive cells);
this platelet population was then analyzed for red fluorescence.
The instrument was calibrated daily using 2 m beads (Becton
Dickinson Immunocytometry Systems). Light scatter and fluo-
rescence data were obtained with gain settings in the logarith-
mic mode, and the data were analyzed with a 2151 Data
Handling System (Ortho Diagnostic Systems). The mean chan-
nel number of fluorescence intensity (mcf) was used a quanti-
tative measure of antibody binding. The flow cytometric assays
were established with the help of Dr. Samuel R. Wellhausen.
200 400 600
Log fluorescence
arbitrary Units
Fig. 1. Effect of stimulation with thrombin (0.1 U/mI for 20 mm) on
platelet surface-bound thrombospondin as assessed by binding of
anti-TSP monoclonal antibody. Symbols are (—) control Ab; anti-TSP
binding to non-stimulated (—.
—); thrombin stimulated ('' ')platelets.
SDS-polyacrylamide gel-electrophoresis (SDS-PAGE) and
immunobl oiling
Samples from uremic and control platelets were prepared by
exposing platelets suspended in Tyrode's buffer, pH 7.5, con-
taining divalent cations (l0 platelets/mi) to 0.5 U/mi of bovine
thrombin (Sigma) for three minutes at 37°C. Phenylmethane-
sulfonylfluoride (PMSF) (1 mM) was then added and samples
were spun at 8000 x g for five minutes. Platelet poiypeptides
were fractionated by SDS-PAGE [21]. Washed platelets were
solubilized with 3% SDS containing 1 mti PMSF and heated for
three minutes at 80°C in the presence of f3-mercaptoethanol.
Proteins were electrophoreticaliy transferred to nitrocellulose
paper at 12 volts for one hour at 25°C (Idea Scientific Company,
Corvallis, Oregon, USA) in pH 8.3 buffer containing 25 mmol/
liter of Tris and 192 mmollliter of giycine. Immunodecoration
was performed with a monospecific polycionai TSP-antibody
(Diagnostica Stago) according to standard methods.
Data analysis
Platelet counts and plasma concentrations of TSP and /3TG
obtained in the hemodialysis studies were corrected for changes
in plasma volume arising from ultrafiltration using concurrent
hematocrit values. This correction was not used for TxB2
because its small size (approximately 370 D) would result in it
being freely filtered by the dialysis membrane and, therefore,
not concentrated by ultrafiltration. Student's I-test for unpaired
data was used to test for differences between normal controls
and patients, predialysis. Analysis of variance for repeated
measures was used to test whether or not a given parameter
changed with time during hemodialysis or ex vivo perfusion
time. The significance of the change in a parameter between the
dialyzer outlet and inlet was determined by Student's i-test for
paired data. Two-way analysis of variance was used to compare
TSP and I3TG release by normal and uremic platelets. Where a
significant difference was found (P < 0.05), differences between
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Hemodialysis
patientsa
Normal
controls
Plasma 5,0 0.4 (N = 16)b 10.1 2.8 (N = 15)
thrombospondin
ng/ml
Plasma 172 22 (N = 16)C 75 14 (N = IS)
/3-thromboglobulin
ng/ml
Platelet count 103/,.d 243 19 (N 13) 209 18 (N = 9)
Platelet surface-bound
thrombospondin mcf'
Non-stimulated 176 27 (N = 12) 130 17 (N = 7)
Thrombin-stimulated 342 28 320 67
Platelet GMP-140
expression mcf1
Non-stimulated 73 3 (N = 7) 69 I (N 4)
Thrombin-stimulated 164 29 182 20
Plasma solute concentrations for the hemodialysis patients are
presented as measured. No correction has been made for the difference
in hematocrit between the patients and the normal controls.
b Significantly less than normal controls, P = 0.042
C Significantly greater than normal controls, P = 0.001d mcf, Mean channel number of fluorescence intensity (Methods)
individual pairs of samples were tested using the Student-
Newman-Keuls procedure. Many baseline plasma TSP concen-
trations were at the lower limit of detection (4 nglml), giving rise
to data that was not normally distributed. In these instances,
appropriate non-parametric tests (Mann-Whitney U test,
Wilcoxon signed rank test) were used. All statistical testing was
performed using the SPSS/PC+ statistical package (SPSS mc,
Chicago, Illinois, USA). Data are presented as mean SEM for
N observations.
Results
Baseline plasma thrombospondin and f3-thromboglobulin,
platelet surface-bound thrombospondin, and platelet GMP-
140 (CD62) expression
In comparison to normal controls, plasma TSP concentra-
tions were significantly lower in the hemodialysis patients,
pre-dialysis (P = 0.047, Table 2). In contrast, plasma /3TG
concentrations were significantly elevated in the hemodialysis
patients compared to the normal controls (P = 0.001, Table 2).
There was no correlation between TSP and flTG in either
group.
Platelet counts in the hemodialysis group were not different
from those in the control group (Table 2). As shown in Figure 1,
non-stimulated control platelets demonstrated essentially no
surface-bound TSP. Activation with thrombin (0.1 U/mI) for 20
minutes at 37°C resulted in a marked increase in surface-bound
TSP (Fig. 1, Table 2). Comparable results were obtained for
platelets from hemodialysis patients (Table 2). The pattern of
platelet GMP-140 expression was similar to that of surface-
bound TSP; again, there were no differences between platelets
from hemodialysis patients and controls (Table 2).
Fig. 2. Changes in plasma thrombospondin concentrations in blood
entering (•) and leaving (V) the dialyzer during hemodialysis. Data are
presented as mean SEM for 9 experiments. A significant increase in
thrombospondin concentration between the dialyzer outlet and inlet is
indicated by *,
Hemodialysis studies
Administration of heparin did not affect the plasma concen-
trations of either TSP or /3TG in the hemodialysis patients (data
not shown). Arterial plasma TSP concentrations increased
transiently during the first three minutes of dialysis and then
returned to pre-dialysis levels (Fig. 2). After 15 minutes, arterial
TSP concentrations again increased and were significantly
greater than pre-dialysis values after 240 minutes (P = 0.004,
Fig. 2). Plasma TSP concentrations leaving the dialyzer were
greater than arterial values at all time points after five minutes.
A similar pattern was observed for changes in plasma t3TG
during dialysis (Fig. 3). Arterial plasma /3TG concentrations
increased significantly during dialysis (P = 0.001), with the
dialyzer inlet to outlet concentration difference achieving sig-
nificance after 30 minutes of dialysis. In contrast to both TSP
Table 2. Plasma thrombospondin and /3-thromboglobulin, platelet 16
count, surface-bound thrombospondin, and GMP-l40 expression in
normal subjects and hemodialysis patients, pre-dialysis 14
12
10
8
S
'a
C0
a.
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.0
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-cI-
6
Time, minutes
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Fig. 3. Changes in plasma /3-thromboglobulin concentrations in blood
entering (•)and leaving (V) the dialyzer during hemodialysis. Data are
presented as mean SEM for 9 experiments. A significant increase in
/3-thromboglobulin concentration between the dialyzer outlet and inlet
is indicated by *
0 10 20
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" five minutes and its magnitude was similar in both the mini-
module and tubing control. Plasma /3TG concentrations were
also increased significantly over baseline controls; however,
unlike TSP, the increase in ffl'G depended significantly on both
time and the presence of the membrane (P = 0.047). Surface-
bound TSP on non-stimulated and thrombin-stimulated plate-
lets exposed to both the cellulose membrane and the control
tubing remained unchanged throughout the ex vivo perfusion
(Table 4).
In vitro studies
Because of the apparent difference in the magnitude of TSP
release by normal and uremic platelets following exposure to a
cellulosic dialysis membrane (Fig. 2 and 5), the release of TSP
30 240 by normal and uremic platelets in response to thrombin stimu-
lation was examined in vitro. In the control group, thrombin
activation significantly increased plasma levels of TSP and JITG
(Table 5). The release of TSP from the platelets of hemodialysis
patients was significantly less than that from normal platelets (P
= 0.034), and essentially no increase in plasma /3TG was seen
(Table 5). Lysis of platelets in PRP by Triton X-l00 revealed
that hemodialysis patients tended to have lower total platelet
TSP stores than normal, although this difference was not
significant (P = 0.149). A reduction in TSP release by platelets
from hemodialysis patients was also suggested by the results of
the irnmunoblotting studies. As shown in Figure 6, immunoblot-
ting of identical amounts of SDS-PAGE-separated release pro-
teins from platelets obtained from the hemodialysis patients
showed a distinctly weaker immunoreaction than release pro-
teins from normal platelets. Probing of total platelet proteins for
TSP antibody binding revealed an increased number of immu-
noreactive bands with greater molecular mobility for the hemo-
dialysis patients compared to the normal controls (Fig. 6).
Discussion
Multiple, complex changes occur in hemostatic mechanisms
during hemodialysis. Since TSP is suggested to play an impor-
tant role in platelet aggregation and primary hemostasis [6—tO],
changes in its plasma concentration may be a useful indicator of
thrombogenic events occurring during hemodialysis.
In agreement with previous reports [22, 23j, f3TG concentra-
tions were significantly increased in hemodialysis patients,
pre-dialysis, compared to normal controls (Table 2). In con-
trast, plasma concentrations of TSP were significantly de-
creased in hemodialysis patients, pre-dialysis, when compared
to normal subjects (Table 2). Baseline values of plasma TSP
obtained in this study were less than those reported in earlier
studies [11—13]. The reasons for this discrepancy are not
known, but may include differences in the antisera or TSP
standards used previously as has been reported for the analysis
of other a-granule proteins [24]. The amount of surface-bound
TSP and GMP-140, a-granule proteins released and expressed
on the platelet plasma membrane following activation, did not
differ between the two groups, either for non-stimulated or
thrombin-stimulated platelets (Table 2). The latter finding sug-
gests that the a-granule release reaction is not altered in the
platelets of hemodialysis patients.
Increased production of TxB2 [25—27] and release of the
platelet specific a-granule protein, pTG, [22, 28, 29] have been
repeatedly reported to occur during hemodialysis. Our studies
*
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Fig. 4. Changes in plasma thromboxane B2 concentrations in blood
entering (•) and leaving (V) the dialyzer during hemodialysis. Data are
presented as mean SEM for 6 experiments. A significant increase in
thromboxane B2 concentration between the dialyzer outlet and inlet is
indicated by
0 10 20
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and /31G. arterial TxB2 concentrations increased promptly
following initiation of dialysis (P = 0.001), plateauing at approx-
imately 250% of the pre-dialysis value after five minutes of
dialysis (Fig. 4). Dialyzer outlet concentrations of TxB2 were
significantly greater than arterial concentrations at all sampling
times.
Arterial platelet counts changed significantly (P = 0.01) with
time of dialysis. The magnitude of the change was small,
however, being no greater than 5% at any sampling time (Table
3). There was no change in platelet count between the inlet and
outlet of the dialyzer at any sampling time. Administration of
heparin did not affect the amount of platelet surface-bound
TSP; for example, the level of surface-bound TSP following
thrombin stimulation was 335 48 mcf in the absence of
heparin and 278 60 mcf following heparin administration (N =
7, NS). The amount of surface-bound TSP on platelets from
arterial blood remained unchanged throughout dialysis, both for
non-stimulated and thrombin-stimulated cells (Table 3). The
thrombin-induced increase in surface-bound TSP, however, did
show a small, but significant (P = 0.048) dependence on dialysis
time, increasing from 123 12 channels, pre-dialysis, to 200
35 channels by five minutes and remaining at that level,
thereafter. The major contribution to the change in the throm-
bin-induced increase in surface-bound TSP appeared to arise
from a decrease in the non-stimulated level, although this
decrease was not significant. Transit of platelets through the
dialyzer had no effect on the level of surface-bound TSP in
either non-stimulated or thrombin-stimulated cells. Platelet
GMP-140 expression on both non-stimulated and thrombin-
stimulated platelets was unaffected by dialysis (Table 3).
Ex vivo studies
Plasma TSP and /3TG levels during ex vivo blood perfusion of
mini-modules containing cellulose membranes are shown in
Figure 5. Plasma TSP concentrations were increased over
baseline levels at the outlet of both the tubing control and the
mini-module. This increase in concentration was evident after
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Table 3. Changes in platelet count, surface-bound thrombospondin, and GMP-140 expression during hemodialysis
Pre-HD
Time of dialysis miii
3 5 15 30 240
Platelet count 103/1.d (N = 9)
Inlet (arterial) 212 19 221 16 218 18 199 17 201 16 217 22
Outlet 217 20 219 24 202 20 191 18
Platelet surface-bound thrombospondin mcf (N = 8)
Non-stimulated
Inlet (arterial) 200 37 134 32 140 35 144 49 192 28 123 28
Outlet 168 25 141 25 170 35 160 29
Thrombin-stimulated
Inlet (arterial) 323 40 311 45 351 44 317 59 335 61 345 45
Outlet 296 41 329 39 377 40 289 50
Platelet GMP-l40 expression mcf (N = 5)
Non-stimulated
Inlet (arterial) 77 4 74 3 74 3 70 3
Outlet 82±1 77±3
Thrombin-stimulated
Inlet (arterial) 208 39 195 12 210 23 204 33
Outlet 190 26 192 33
a mcf, Mean channel of fluorescence intensity (Methods)
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Fig. S. Changes in plasma thrombospondin (A) and f3-thromboglobulin(B) concentrations leaving the membrane module (A) and tubing
control (•) following ex vivo perfusion with normal blood. Data are
presented as mean SEM for 5 experiments.
confirm these findings and, in addition, show significant in-
creases in arterial plasma TSP concentrations, and in plasma
TSP concentrations between the inlet and outlet of the dialyzer,
in the first 30 minutes of dialysis (Fig. 2). The concurrent
increases in TSP and f3TG across the dialyzer suggest that
Table 4. Surface-bound thrombospondin on platelets following ex
vivo perfusion of mini-modules containing cellulose membrane or
tubing control
Surface-bound thrombospondin mcf (N = 3)
Tubing control Membrane module
Non-
stimulated Activated
Non-
stimulated Activated
Baseline
Perfusion time
minutes
3
5
10
20
30
167 9 361 55
136 10 312 7
138 10 280 15
131 14 367 55
134 18 377 57
124 14 383 21
174 12 521 88
185 32 325 36
148 12 398 50
166 18 379 72
173 55 338 25
Table 5. Effect of thrombin stimulation on thrombospondin and /3-
thromboglobulin release from platelets of normal controls and
hemodialysis patients, pre-dialysis
Thrombin concentration U/mI Total platelet
content0 0.005 0.1
Thrombospondin ng/108 platelets (N = 4)
Normal 2.7 0.5 5.6 1.4 6.1 1.2 5580 1017
Pre-dialysis 2.5 0.3 2.9 0.4 3.8 0.5 3475 617
/3-thromboglobulin ng/108 platelets (N = 4)
Normal 20 5 67 23 72 20 9978 3196
Pre-dialysis 65 8 60 9 66 5 12531 3336
dialyzer-induced platelet activation is the most likely mecha-
nism for the increases in plasma TSP concentration. Although
monocytes may also serve as a source of TSP [6], release of
TSP by activated monocytes seems unlikely to account for the
increases in plasma TSP seen in this study. Firstly, after 15 and
30 minutes of dialysis, when the increases in plasma TSP
concentration between the inlet and outlet of the dialyzer were
greatest (Fig. 2), there were very few circulating monocytes as
a mcf, Mean channel of fluorescence intensity (Methods)
2 3
p
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Fig. 6. Immunoblot of total proteins and release
proteins from platelets of a normal control (total
proteins: lane I, release proteins: lane 4), patient 4
(total proteins: lane 2, release proteins: lane 5) and
patient 9 (total proteins: lane 3, release proteins: lane
6). Samples were run under reducing conditions and
each lane of the blotted get contained equal amounts of
total platelet protein (30 g) or release proteins (20 tg).
Standard molecular weight markers were: myosin (205
kD), 13-galactosidase (116 kD), phosphorylase B (97.4
kD), and bovine albumin (66 kD).
a consequence of the complement-induced pulmonary seques-
tration of leukocytes which occurs during dialysis with cellulo-
sic membranes [301. Blood monocyte counts at the inlet to the
dialyzer were 99 18 and 149 42 cells/pi after 15 and 30
minutes of dialysis, respectively, compared to platelet counts of
199,000 17,000 and 201,000 16,000 cells/pi, respectively.
Secondly, Jaffe, Ruggiero and Falcone [31] have shown that,
while monocytes are able to synthesize and secrete TSP, they
do not store TSP, either intracellularly or in an extracellular
matrix. Thus, TSP release by monocytes depends on protein
synthesis which could not occur in the 20 seconds it takes a
monocyte to pass through the dialyzer. Further, it is unlikely
that the increase in plasma TSP concentrations resulted from an
improvement in uremia, since plasma TSP concentrations also
increased during passage of blood through the mini-modules of
the ex vivo system; a circumstance free from the effects of
uremia.
Plasma concentrations of TSP and /3TG increased transiently
during the first five minutes of dialysis, followed by a more
sustained increase after 15 minutes (Fig. 2 and 3). While the
initial increases did not reach statistical significance, they were
consistently seen and suggest that the platelet response to
extracorporeal circulation may be biphasic. At present, we can
only speculate on the mechanisms of such a biphasic response.
However, a transient release of platelet activating factor (PAF)
in the first minutes of dialysis has been described [32], suggest-
ing a role for this strong agonist in the initial phase of platelet
degranulation. The rapid appearance of TxB2 (Fig. 4), followed
later by increases in TSP and Ifl'G, suggests that the platelet
a-granule release occurring after 15 minutes of dialysis may be
mediated by thromboxane A2, the active precursor of TxB2
[33].
Since a significant fraction of TSP released during platelet
activation is immediately bound to the platelet plasma mem-
brane, surface-bound TSP has been suggested to be a better
marker of platelet activation than plasma concentrations [13].
Accordingly, we used flow cytometry to measure intra-diatytic
changes in platelet surface-associated TSP and GMP-l40, an-
other a-granule protein which becomes surface expressed fol-
lowing platelet activation [18]. We could not detect any change
in the amount of surface-bound TSP or GMP-l40 on platelets
from arterial or venous blood samples during dialysis (Table 3),
either on non-stimulated or on thrombin-stimulated cells.
The lack of an apparent increase in surface-bound TSP and
GMP-140 during hemodialysis in the face of increased plasma
concentrations of TSP and /3TG is not easily explained. Similar
results were found in the ex vivo studies (Fig. 5, Table 4),
suggesting that the lack of TSP expression during dialysis was
not the result of uremia. An increase in plasma levels of
a-granule proteins without a significant increase in platelet-
bound TSP has also been reported for cardiopulmonary bypass
[34]. Heparin, which is used as an anticoagulant in both
hemodialysis and cardiopulmonary bypass, binds to TSP and
might either mask the epitope recognized by the anti-TSP
monoclonal antibody or interfere with TSP binding to its
receptor. However, preliminary results [35] argue against this
mechanism. Alternatively, platelets with increased surface-
bound TSP or GMP-140 may have aggregated and adhered to
the dialysis membrane, thereby leaving the circulation and
escaping detection. This explanation is consistent with the
suggestion of Musial et al [36] that release of a-granule constit-
uents does not occur until after activated platelets have adhered
to the surface of the extracorporeal circuit. Recovery and
analysis of platelets adhering to the membrane will be needed to
examine this possibility.
We used an ex vivo model of hemodialysis [16, 17] to further
characterize TSP release during blood flow through cellulose
dialysis membranes. This model closely simulates hemodialy-
sis, but uses normal blood. Plasma TSP increased immediately
following initiation of blood perfusion (Fig. 5). Strikingly,
plasma TSP levels obtained in the ex vivo experiments were
about twofold greater than those observed during hemodialysis.
This difference cannot be explained by the greater plasma
volume associated with the anemia of chronic renal failure.
Although hematocrits were greater in the ex vivo experiments
than in the hemodialysis studies (40.1 2.1 vs. 29.7 0.5), this
difference could only lead to a 17% difference in TSP concen-
trations following an equivalent degree of TSP release. In
addition, plasma concentrations of I3TG also increased to a
similar extent during ex vivo perfusion and hemodialysis (Figs.
3 and 5). Further, since there was a significant correlation
between TSP and I3TG concentrations in the ex vivo experi-
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Table 6. Increases in plasma concentrations of thrombospondin and f3-thromboglobulin between dialyzer inlet and outlet in patients receiving
and not receiving rHuEPO
Time of dialysis mm
1 3 5 15 30
Thrombospondin ng/ml
With rHuEPO —1.0 1.4 1.8 1.2 4.8 1.5 3.1 1.3 4.3 1.9
Without rHuEPO —2.0 2.0 0.3 0.4 0.0 0.0 2.4 2.4 4.0 2.6
p-thromboglobulin ng/ml
With rHuEPO —4 39 I 34 Ill 46 55 43 154 39
Without rHuEPO —7 16 2 5 4 2 5 13 87 55
Data are presented as mean SEM for N = 5 (with rHuEPO) or N = 4 (without rHuEPO).
ments (Pearson correlation coefficient = 0.7863, P = 0.001), it
seems unlikely that the higher plasma TSP concentrations seen
in the ex vivo experiments were due to TSP release from other
blood cells, such as monocytes [61. Therefore, we conclude that
the platelets of hemodialysis patients may have a reduced
ability to release TSP, as has been suggested previously for
J3TG [37].
To further investigate TSP release from platelets of hemodi-
alysis patients, whole blood was stimulated with thrombin in
vitro and the resulting plasma levels of TSP and /3TG deter-
mined. The results of these experiments (Table 5) showed a
blunted response to thrombin stimulation by the platelets of
hemodialysis patients compared to those of normal subjects,
confirming the results of the dialysis studies. Surface-bound
TSP on activated platelets did not differ between the two groups
(Table 2), suggesting that the decreased TSP release by platelets
of hemodialysis patients resulted from a reduction of TSP
stores, rather than an impaired release reaction. A reduction in
TSP stores is also supported by the immunoblots (Fig. 6), which
show a diminished immunoreactive band for TSP in the releas-
ate from platelets of hemodialysis patients compared to normal
subjects. Interestingly, total platelet proteins from the dialysis
patients contained a number of TSP immunoreactive bands with
greater molecular mobility (Fig. 6). The presence of these bands
could be due to increased intra-platelet protease activity or
impaired TSP biosynthesis, as has been suggested to occur in
patients with thrombocythemia [38].
It has been demonstrated that treatment with recombinant
human erythropoietin (rHuEPO) ameliorates the hemostatic
disorders associated with uremia [39]. Comparison of the in-
creases in plasma TSP and I3TG concentrations between the
dialyzer outlet and inlet for patients receiving and not receiving
rHuEPO showed them to be greater for the patients receiving
rHuEPO (Table 6), although the differences did not quite reach
statistical significance (P = 0.057 and P 0.114 for /3TG and
TSP, respectively). Why rHuEPO should improve platelet
function is unclear. On the one hand, preliminary studies
suggest that rHuEPO may impact directly on platelets. Sakagu-
chi et al [40] have shown that rHuEPO increases megakarypoie-
sis in vitro, while Van Geet et al [41], studying uremic children
treated with rHuEPO, found improved aggregation and higher
concentrations of intracellular calcium following thrombin stim-
ulation of isolated platelets. On the other hand, are reports
suggesting the normalization of prolonged bleeding times fol-
lowing correction of anemia is mediated by the increase in
erythrocyte numbers, either through hemodynamic mecha-
nisms [42] or transcellular metabolism involving erythrocyte
effects on eicosanoid release by platelets [43]. The mechanisms
by which rHuEPO affects platelet function, and whether or not
improved function results in platelets being more easily ac-
tivated during hemodialysis, remain unknown. However,
rHuEPO therapy is now a common part of the treatment of
end-stage renal disease and, if confirmed, any rHuEPO-induced
improvement in platelet function could pose problems in terms
of dialyzer blood loss and blood access thrombosis.
The clinical significance of these apparent abnormalities in
TSP release remains unknown. Further studies are currently
underway to extend our observations to determine whether the
observed decrease in TSP release results from uremia, per Se,
or is a consequence of repeated hemodialysis. Also, since the
plasma concentration of TSP is independent of renal catabolism
and heparin infusion [7, 12], conditions which affect plasma
levels of the a-granule proteins, J3TG and platelet factor 4,
respectively [Il, 12], TSP may be a useful marker of platelet
a-granule release in renal failure and hemodialysis.
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